SCHEMBL1765099

SCHEMBL1765099

Cc1nc(-c2ccc(C)c(F)c2)cs1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
GAA P10253 4/20 0.58
RECQL P46063 3/20 0.58
KDM4E B2RXH2 3/20 0.58
MAPT P10636 2/20 0.58
POLB P06746 2/20 0.58
HPGD P15428 1/20 0.58
ESR2 Q92731 1/20 0.58
TSHR P16473 1/20 0.53
RAB9A P51151 5/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
NPC1 O15118 4/20 0.53
HSD17B10 Q99714 1/20 0.53
ROCK2 O75116 1/20 0.51
PIM1 P11309 1/20 0.51
GSK3B P49841 1/20 0.51
AURKB Q96GD4 1/20 0.51
GFER P55789 1/20 0.51
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764691 0.88 ALDH1A1 (0.60) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL8256648 0.86 GAA (0.58) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL1689576 0.85 RAB9A (0.66) ALDH1A1KDM4EMAPTPOLBHPGD
SCHEMBL1764528 0.84 GAA (0.64) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL19627004 0.83 ABL1 (0.59) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL13367649 0.81 ALDH1A1 (0.74) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL8221631 0.81 GAA (0.53) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL19626589 0.81 CYP11B2 (0.56) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL12021983 0.80 GAA (0.55) ALDH1A1GAARECQLKDM4EMAPT
SCHEMBL12021849 0.80 RECQL (0.58) ALDH1A1GAARECQLKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288435-B2 2-aza-bicyclo[3.1.0]hexane derivatives as orexin receptor antagonists ACTELION PHARMACEUTICALS LTD. (CH) 2012-10-16 US disclosed
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124636-A1 2-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, CNR1 ALDH1A1 807/4885GAA 3257/4885RECQL 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.